Cost-effectiveness of a technology-supported multimodal prehabilitation program in moderate-to-high risk patients undergoing lung cancer resection: randomized controlled trial protocol

Anael Barberan-Garcia1,2,3*, Ricard Navarro-Ripoll4, David Sánchez-Lorente5, Jorge Moisés-Lafuente1, Marc Boada5, Monique Messaggi-Sartor1,2, Laura González-Vallespi6, Mar Montané-Muntané4, Xavier Alsina-Restoy1, Betina Campero7, Manuel Lopez-Baamonde4, Barbara Romano-Androni7, Rudith Guzmán5, Antonio López4, Maria Jose Arguis4, Josep Roca1,2,3 and Graciela Martinez-Palli2,4

Abstract

Background: Multimodal prehabilitation is a preoperative intervention with the objective to enhance cancer patients’ functional status which has been showed to reduce both postoperative morbidity and hospital length of stay in digestive oncologic surgery. However, in lung cancer surgery patients further studies with higher methodological quality are needed to clarify the benefits of prehabilitation. The main aim of the current protocol is to evaluate the cost-effectiveness of a multimodal prehabilitation program supported by information and communication technologies in moderate-to-high risk lung cancer patients undergoing thoracic surgery.

Methods: A Quadruple Aim approach will be adopted, assessing the prehabilitation program at the following levels: i) Patients’ and professionals’ experience outcomes (by means of standardized questionnaires, focus groups and structured interviews); ii) Population health-based outcomes (e.g. hospital length of stay, number and severity of postoperative complications, peak oxygen uptake and levels of systemic inflammation); and, iii) Healthcare costs.

Discussion: This study protocol should contribute not only to increase the scientific basis on prehabilitation but also to detect the main factors modulating service adoption.

Trial registration: NCT04052100 (August 9, 2019).

Keywords: Prehabilitation, Exercise training, Physical activity, Nutritional optimization, Smoking cessation, Cognitive behavioral therapy, Postoperative morbidity
Background

Complete surgical resection remains the best curative option in the treatment of early stage lung cancer. However, many resectable tumors occur in patients with abnormal lung function, usually due to the use of tobacco, having chronic obstructive pulmonary disease (COPD) and/or atherosclerotic vascular disease as underlying comorbidities. Precisely, this group of patients has an increased risk of postoperative complications and of being considered inoperable [1, 2]. Preoperative identification of patients with increased surgical risk [3] should be followed by strategies to prevent potential postoperative complications by reducing their incidence and/or severity, and thus minimizing their clinical and economic impact. Therefore, the implementation of effective preventive interventions is an important milestone to achieve due to the current economic context.

Multimodal prehabilitation is a preoperative intervention with the objective to enhance cancer patients’ functional status in order to improve clinical postoperative outcomes [4]. The main interventions included in prehabilitation programs are exercise training, nutritional optimization, psychological support and behavior change, among others. In this regard, prehabilitation has been shown to be a promising intervention to enhance aerobic capacity consequently reducing both postoperative morbidity and hospital length of stay, not only in digestive cancer patients [5–7], but also in cardiovascular surgery [8, 9]. However, in lung cancer patients undergoing thoracic surgery, further studies with larger samples and higher methodological quality are needed to clarify the potential benefits of prehabilitation [10]. It is important to highlight, that lung cancer patients candidates for thoracic surgery are more likely to benefit from prehabilitation since they usually have a significant reduction in functional capacity from multifactorial origins, namely: i) Pulmonary limitations due to COPD [11]; ii) Lean mass deficit due to systemic effects derived from both underlying cardiopulmonary chronic conditions [12, 13] and cancer [14] and/or produced by the sedentary lifestyle presented by these patients [15]; iii) Functional alterations of cardiopulmonary comorbidities [2]; iv) Side effects of the neoadjuvant therapy (radiotherapy/chemotherapy/immunotherapy); and, v) The state of anxiety-depression associated with the diagnosis and surgery [16]. Therefore, the implementation of multimodal prehabilitation programs addressing these multifactorial etiologies in lung cancer patients undergoing thoracic surgery is of paramount importance.

The main aim of the current protocol is to evaluate the cost-effectiveness of a multimodal prehabilitation program supported by information and communication technologies (ICT) in moderate-to-high risk lung cancer patients undergoing thoracic surgery. Moreover, further secondary assessments, within a Quadruple Aim approach [17, 18], will also be performed, including: i) Patients’ experience outcomes; ii) Population health-based outcomes; iii) Costs from the hospital perspective; and, iv) Healthcare professional perspective outcomes. Additionally, an ancillary aim of the study will be to refine the ICT supporting the program in order to prepare large-scale deployment of a sustainable and modular multimodal prehabilitation services at regional (Catalonia) and European level [19].

Methods / design

Study design and population

This study is a single blind randomized controlled trial. Patients will be randomized (computer-generated random numbers) on a 1:1 ratio, either to: i) a control group which will follow the standard of care established by the protocols used in our hospital; and, ii) an intervention group which, besides the standard preoperative management, will undergo a personalized multimodal prehabilitation program at Hospital Clinic de Barcelona (Catalonia) (Fig. 1). The sample of subjects will include moderate-to-high risk lung cancer patients candidates to thoracic surgery. Inclusion criteria are the following: i) Predicted postoperative forced expiratory volume in the first second and/or predicted postoperative lung diffusion capacity for carbon monoxide < 60%, and/or; ii) American Society of Anesthesiologists (ASA) classification [20] 3–4; and/or, iii) age ≥ 75 years old. Exclusion criteria are: i) Undergoing non-elective surgery; ii) known metastatic disease before surgery; iii) unstable respiratory or cardiac condition; iv) cognitive or locomotive limitations precluding adherence to the program. The study protocol and informed consent have been evaluated and accepted by the Medical Research Ethics Committee at Hospital Clinic de Barcelona (HCB/2018/1138). The study protocol is displayed at https://clinicaltrials.gov/ct2/show/NCT04052100.

Procedures

Standard care

The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool [21] ≥2).

Multimodal prehabilitation program

Besides the standard preoperative management aforementioned, the intervention group will undergo a
multimodal prehabilitation program. The interventions included will be patient-centered aiming to optimize patients’ preoperative health status while enhancing their empowerment and engagement. Most of the components of the program will be community-based and will be supported by a mobile solution and a technological platform for patients’ management. The main components of the program are described below.

(i) Supervised exercise training program: This program will consist in ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training performed on a stationary cycle-ergometer (Technogym® Excite Bike; Cesena; Italy) and strength muscular training (Technogym® Plurima Multistation Wall; Cesena; Italy). Patients will undergo 3 sessions per week. Each endurance training session will include 5 min of warm up, 37 min of interval training, and 5 min of cool down. The interval training will combine 3 min of high-intensity pedaling and 3 min of active rest. Work-rate progress during the program will be tailored on an individual basis, according to patients’ symptoms (modified Borg scale) [22], to maximize the training effect. The strength training session will consist in 3 series of 15 repetitions for each of the following exercises: i) horizontal rowing; ii) pectoral press; and, iii) quadriceps bench. Weight progress during the program will be adapted to patients’ tolerance with the final aim of maximizing the training effect.

(ii) Personalized program to promote physical activity: This will be a pedometer-based program using a physical activity tracker linked to a mobile app. Main physical activity-related functionalities of the technological solution are: i) Self-monitoring of the number of steps per day and percentage of accomplishment of the objective; ii) A daily motivational message; iii) Positive reinforcement once objective of daily steps is achieved; and, iv) Exercise and physical activity educational material. International recommendations for physical activity based on the number of daily steps [23] will serve as a theoretical framework regarding the generation of goals. All the information monitored using the mobile solution will be registered in a technological platform serving as a professional backend where it will be checked and assessed by a specialized physiotherapist.

(iii) Nutritional optimization program: Patients will receive personalized dietary counseling from a registered dietician. Based on the initial evaluation, patients will receive recommendations of a healthy balanced diet or a diet adapted to their digestive symptoms, if present. The daily amount of protein intake capable of producing a positive nitrogen balance in these patients is estimated to be close to 2 g·Kg$^{-1}$·day$^{-1}$. This protein intake (1.5–2 g·Kg$^{-1}$·day$^{-1}$)
1·day−1) will be ensured in patients with adequate kidney function, distributed in three main daily meals, by means of food enrichment, and/or nutritional supplementation such as whey protein powder or casein. Sufficient caloric supply will be ensured as a mean to guarantee proper protein utilization. Moreover, alcohol intake abstinence will be highly recommended and professional help offered if required. Moreover, personalized educational material as well as follow-up surveys will also be provided using the mobile app. As well as in the physical activity promotion program, the nutritional information will be registered in the technological platform and assessed by the dietician.

(iv) Smoking cessation program: The treatment will consist in the use of both cognitive behavioral intervention and pharmacological therapy either by varenicline and/or nicotine replacement therapies. A weekly monitoring will be performed to evaluate the evolution of their abstinence symptoms and craving control.

(v) Cognitive behavioral therapy: The intervention will consist on weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment. The main objectives of the cognitive behavioral therapy will be to reinforce patients’ motivation, to provide coping strategies to manage stress and to foster patients’ engagement for healthy lifestyles (i.e. physical activity, nutritional habits and smoking cessation) according to the program objectives. Group sessions will be complemented by providing educational material, audio guides for coping strategies exercises and motivational text messages using the mobile solution. Patients with comorbid psychopathology will be addressed to a specialized service.

Sample size calculation and statistical analysis
Sample was calculated with GRANMO program [35] taking hospital length of stay reduction as the main outcome measure. Accepting an \( \alpha \)-risk of 0.05 and a \( \beta \)-risk<0.2 in a bilateral contrast and assuming a 15% of follow-up losses and a standard deviation of 3.1, 79 patients in each group will identify a statistically significant reduction ≥1.5 days of length of hospital stay.

Data will be analyzed to explore and assess the effect of the intervention on the use of health resources and clinical impact by comparing the intervention group with the control group using hypothesis tests. The characteristics of the intervention group and the control group will be compared using Student’s t-test, Kruskal-Wallis or Chi\(^2\), according to the distribution of the variables. The effect of the intervention will be studied by intention to treat through regression analysis (linear, logistic, Cox or Poisson, depending on the distribution of the variable), including the exposure to the intervention as the main variable and as co-variables those in which the intervention group and the control group are different at baseline, if there were any present. A cost-effectiveness study will be carried out from the perspective of the hospital, taking into account the costs of the

Study variables
As stated in the introduction of the present manuscript, study outcome variables will follow a Quadruple Aim approach [17, 18]. Firstly, from the patients’ experience perspective, main outcome variables included will be person centeredness by the Person Centered Coordinated Experience Questionnaire [24] and continuity of care by the Nijmegen Continuity Questionnaire [25]. Moreover, focus groups and structured interviews will be also undertaken to identify facilitators and barriers to prehabilitation. Secondly, population health-related outcome variables will be hospital and intensive-care length of stay, number and severity of postoperative complications [26], number of hospital readmissions and emergency visits at 30 days, physical activity using Yale Physical Activity Survey (YPAS) [27], aerobic capacity measured by a standard cardiopulmonary exercise test, self-perceived health status using the Short-Form (36) health survey (SF-36) [28], anxiety and depression levels using the Hospital Anxiety and Depression score (HAD) [29], lean mass index measured by bioimpedanciometry, and levels of systemic inflammation [30] by determinations of C-reactive protein (CRP), ultrasensitive CRP, TNF-\( \alpha \) Factor, \( \gamma \)-interferon and interleukins 6 and 10. Thirdly, hospital costs will be assessed, including: i) Patient-chargeable costs (i.e. pharmacy and blood bank); ii) Tariff-chargeable costs (i.e. medical care, diagnostic techniques, laboratories, specialist consultations, hospital length of stay and hostelry); and, iii) Other costs (i.e. support and structural costs). Last, but not least, health-care professionals’ perspective will be assessed by Advancing Care coordination and Telehealth deployment at Scale (ACT@Scale) questionnaire [31]. Professionals’ perspectives (i.e. healthcare professionals, policy makers, healthcare companies’ representatives and health technology agents) will be also assessed by means of focus groups and structured interviews.

Descriptive variables will include socio-demographic, environmental, and interpersonal data, smoking status, alcohol intake, comorbidities, pulmonary function tests [32–34] and arterial blood gases. All data will be collected in a technological platform.
intervention and the expenses related to the disease during the follow-up (30 days).

Discussion

The current manuscript reports a study protocol to assess the impact of multimodal prehabilitation in moderate-to-high risk patients undergoing lung cancer resection within a Quadruple Aim approach [17]. In this regard, the comprehensive evaluation strategy presented will provide novel information on prehabilitation at different levels, contributing to increase the scientific basis on the field, and also potentially detecting the main factors that modulated service adoption in the clinical practice.

It is well-known that novel healthcare services within an integrated care approach, such as prehabilitation in cancer surgery, are applied in complex patients and settings entailing the connectivity, alignment, and collaboration of several stakeholders and healthcare tiers. Therefore, this protocol also envisages the assessment of the practicalities for service accessibility, sustainability and scalability by means of focus groups and structured interviews with patients, caregivers and professionals.

The community setting has to be acknowledged as a cornerstone for the adoption and scalability of prehabilitation programs. The link between the hospital and the community setting should be possible thanks to ICT acting as enabling tools at three levels: monitoring, communication and patient management. In this protocol we postulate a mobile phone solution and a technological platform to optimize patients’ adherence to the work plan.

Finally, besides traditional prehabilitation outcomes (i.e. hospital length of stay, postoperative complications, cost-effectiveness), the protocol reported in this article will also explore novel aspects in the field, such as the role of systemic inflammation as a potential biomarker of prehabilitation response [30].

The approach of this study protocol should contribute to generate recommendations for transferability and refinement of prehabilitation and perioperative cancer care.

Abbreviations

ACT@Scale: Advancing Care coordination and Telehealth deployment at Scale; ASA: American Society of Anesthesiologists; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; SF-36: Short-Form (36) health survey; HAD: Hospital Anxiety and Depression score; ICT: Information and communication technologies; YPAS: Yale Physical Activity Survey

Acknowledgements

No applicable.

Authors’ contributions

AB-G wrote the first draft of the manuscript. AB-G also contributed to the study design and approved the final version of the manuscript. RN-R, DS-L, JM-L, MB, MM-S, LG-V, MM-M, XA-R, BC, ML-B, BR-A, RG, AL, MJ-A, JR and GM-P contributed to the study design and contributed to and approved the final version of the manuscript.

Funding

This work was supported by the European Commission (PAPIRIKA EIT-Health-IBD-19365, CONNECTICARE H2020-689802, NEXTCARE COMRD15-1-0016); Catalan Foundation of Respiratory Medicine (FLUCAP 2019); Spanish Respiratory Society (SEPAR 2018; Project 791); and, FIS-Smart PI6ES PI18/00841. The funders of the study had no role in study design or writing of the report.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

The study protocol and informed consent have been evaluated and accepted by the Medical Research Ethics Committee at Hospital Clinic de Barcelona (HCB/2018/1138). All patients invited to participate in this trial will be asked to agree and sign the written consent in order to participate in the current study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Respiratory Medicine Department, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Catalonia, Spain. 2August Pi i Sunyer Biomedical Research Institute – IDIBAPS, University of Barcelona (UB), Barcelona, Spain. 3Biomedical Networking Research Centre on Respiratory Diseases (CIBERES), Barcelona, Spain. 4Anaesthesia and Intensive Care Department, Hospital Clinic de Barcelona, Barcelona, Spain. 5Thoracic Surgery Department, Hospital Clinic de Barcelona, Barcelona, Spain. 6Clinical Psychology Department, Hospital Clinic de Barcelona, Barcelona, Spain. 7Endocrinology and Nutrition Department, Hospital Clinic de Barcelona, Barcelona, Spain.

Received: 6 February 2020 Accepted: 6 March 2020

Published online: 12 March 2020

References

1. Postmus PE, Kerr KA, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:v1–21.
2. Brunelli A, Cassivi SD, Fibla J, Halgren LA, Wigle DA, Allen MS, et al. External validation of the recalibrated thoracic revised cardiac risk index for predicting the risk of major cardiac complications after lung resection. Ann Thorac Surg. 2011;92(2):445–8.
3. Bihorac A, Ozrazgat-Baslanti T, Ebadi A, Motaei A, Madkour M, Pardalos PM, et al. MySurgeryRisk. Ann Surg. 2019;269(4):652–62.
4. Scheede-Bergdahl C, Minnella EM, Carl F. Multi-modal prehabilitation: addressing the why, when, what, how, who and where next? Anaesthesia. 2019;74:20.
5. Barberan-Garcia A, Ubré M, Roca J, Lacy AM, Burgos F, Risco R, et al. Personalised Prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial. Ann Surg. 2018;267:1.
6. Barberan-Garcia A, Ubre M, Pascual-Ar gente N, Risco R, Faner J, Balust J, et al. Post-discharge impact and cost-consequence analysis of prehabilitation in high-risk patients undergoing major abdominal surgery: secondary results from a randomised controlled trial. Br J Anaesth. 2019;24:450.
7. Trépanier M, Minnella EM, Paradis T, Awasthi R, Kaneva P, Schwartzman K, et al. Improved disease-free survival after Prehabilitation for colorectal cancer surgery. Ann Surg. 2019;270(3):493–501.
8. Barakat HM, Shahin Y, Khan IJ, McMillum PT, Chetter IC. Preoperative supervised exercise improves outcomes after elective abdominal aortic aneurysm repair. Ann Surg. 2016;264(1):47.
9. Arthur HM, Daniels C, McKelvie R, Hirsh J, Rush B. Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk
10. Rosero ID, Ramírez-Vélez R, Lucía A, Martínez-Velilla N, Santos-Lozano A, Valenzuela PL, et al. Systematic review and meta-analysis of randomized, controlled trials on preoperative physical exercise interventions in patients with non-small-cell lung cancer. Cancers. 2019;11(7):944.

11. O’Donnell OE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–4.

12. Maltais F, Decramer M, Casaburi R, Barrieu E, Burelle Y, Debigaré R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–62.

13. Rehn TA, Munkvik M, Lunde PK, Sjaastad I, Sejersted OM. Intrinsic skeletal muscle alterations in chronic heart failure patients: a disease-specific myopathy or a result of deconditioning? Heart Fail Rev. 2012;17(3):421–36.

14. Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.

15. Watz H, Pitha F, Rochester CL, García-Aymerich J, ZuWallack R, Troosters T, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521–37.

16. Bortolato B, Hyphantis TN, Valpione S, Peinini G, Maes M, Morris G, et al. Depression in cancer: the many biobehavioral pathways driving tumor progression. Cancer Treat Rev. 2017;52:58–70.

17. Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med. 2014;12(6):573.

18. Grocott MPW, Edwards M, Mythen MG, Aronson S. Peri-operative care pathways: re-engineering care to achieve the ‘triple aim’. Anaesthesia. 2019; 74:90.

19. PAPRIKA. Patients empowerment for major surgery @home. [cited 2019 Jun 11]. Available from: https://www.eithealth.eu/paprika.

20. American Society of Anesthesiologists. 2016 relative value guide book: a guide for anesthesia values: American Society of Anesthesiologists 2015; 2016.

21. Malnutrition Advisory Group a SC of B. Malnutrition universal screening tool; 2003.

22. Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377.

23. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, et al. How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act. 2011;8:80.

24. Measures for Person Centred Coordinated Care [Internet]. [cited 2019 Oct 3]. Available from: http://p3c.org.uk/prom-detail/29.

25. Uijen AA, Schellevis FG, van den Bosch WJHM, Mokkink HGA, van Weel C, Schers HJ. Nijmegen continuity questionnaire: development and testing of a questionnaire that measures continuity of care. J Clin Epidemiol. 2011; 64(12):1391–9.

26. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205.

27. Donaire-Gonzalez D, Gimeno-Santos E, Serra I, Roca J, Balcells E, Rodríguez E, et al. Validation of the Yale physical activity survey in chronic obstructive pulmonary disease patients. Arch Bronconeumol. 2011;47(11):552–60.

28. Alonso J, Prieto L, Antó JM. The Spanish version of the SF-36 health questionnaire: an instrument for measuring clinical results. Med Clin. 1995;104(20):771–6.

29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

30. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. de Torres JP, editor. PLoS One. 2012;7(5): e37483.

31. ACT@Scale (2016–19) – Advancing Care Coordination and Telehealth at Scale. [cited 2019 Jun 11]. Available from: https://www.act-at-scale.eu/.

32. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.

33. Wanger J, Clausen J, Coates A, OP F, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005; 26(3):511–22.

34. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. D LCO : adjust for lung volume, standardised reporting and interpretation. Eur Respir J. 2017;50(2):1701144.

35. Marrugat J, Vila J, Pavesi M, Sanz F. Estimation of the sample size in clinical and epidemiological investigations. Med Clin. 1998;111(7):267–76.